# Kathy S. Albain

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/kathy-s-albain/

## Facts

| Field | Value |
| --- | --- |
| Citations | 43,623 |
| Field | Breast Cancer Treatment Studies |
| h-index | 88 |
| i10-index | 238 |
| Last Known Institution | Loyola University Medical Center |
| OpenAlex ID | https://openalex.org/A5059538753 |
| ORCID iD | https://orcid.org/0000-0002-2899-2473 |
| Works | 505 |

## Researcher papers

Showing 12 of 13.

- [Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013](https://scholariq.org/papers/personalizing-the-treatment-of-women-with-early-breast-cancer-highlights-of-the/)
- [Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer](https://scholariq.org/papers/efficacy-of-gefitinib-an-inhibitor-of-the-epidermal-growth-factor-receptor/)
- [Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial](https://scholariq.org/papers/radiotherapy-plus-chemotherapy-with-or-without-surgical-resection-for-stage-iii/)
- [Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial](https://scholariq.org/papers/prognostic-and-predictive-value-of-the-21-gene-recurrence-score-assay-in/)
- [Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer](https://scholariq.org/papers/adjuvant-paclitaxel-and-trastuzumab-for-node-negative-her2-positive-breast/)
- [Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer](https://scholariq.org/papers/effect-of-pembrolizumab-plus-neoadjuvant-chemotherapy-on-pathologic-complete/)
- [Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer](https://scholariq.org/papers/adaptive-randomization-of-veliparib-carboplatin-treatment-in-breast-cancer/)
- [Adaptive Randomization of Neratinib in Early Breast Cancer](https://scholariq.org/papers/adaptive-randomization-of-neratinib-in-early-breast-cancer/)
- [Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials](https://scholariq.org/papers/trastuzumab-for-early-stage-her2-positive-breast-cancer-a-meta-analysis-of-13/)
- [w4200350191](https://scholariq.org/papers/w4200350191/)
- [Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial](https://scholariq.org/papers/durvalumab-with-olaparib-and-paclitaxel-for-high-risk-her2-negative-stage-ii-iii/)
- [Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer](https://scholariq.org/papers/association-of-event-free-and-distant-recurrence-free-survival-with-individual/)

## Researcher topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Researcher university

- [Loyola University Medical Center](https://scholariq.org/institutions/loyola-university-medical-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.